Hello everyone, it’s Dr. Hime here!
The GLP-1 boom has really taken off lately, but with so many types available, it’s hard to know which one is best for you! Which one is the most effective?
In this post, I’ll explain the GLP-1 receptor agonists (GLP-1) currently available in Japan.
First, the only oral option: Rybelsus (Semaglutide)
Since this is an oral medication, its effectiveness is slightly lower compared to others. However, since all other GLP-1 options are injections, Rybelsus is a good choice for those who have trouble with self-injections. That said, the way it must be taken is a bit tricky—it needs to be taken on an empty stomach, and no food or drink is allowed for 30 minutes afterward, which can be difficult to manage, especially in the morning.
Next, the injectable options Ozempic and Wegovy (Semaglutide)
Semaglutide is the top GLP-1 choice in the U.S., a country known for obesity. In Japan, Wegovy was just launched in February 2024, so it’s not widely available yet. However, it is expected to be highly effective for weight loss, as it’s particularly tailored for treating obesity. On the other hand, Ozempic has long been a major player in GLP-1 weight loss treatments and has the added convenience of being administered only once a week.
Now, for Victoza and Saxenda (Liraglutide)
Victoza is primarily used for blood sugar control, while Saxenda is for weight management. This difference mainly comes down to dosage. Victoza is generally used in insured medical care, while Saxenda is sold for weight loss. Although Saxenda requires daily injections, the dosage can be fine-tuned based on your daily condition or plans, such as dining out.
Finally, the Tirzepatide options: Mounjaro and Zeph-Bound
In addition to GLP-1 receptor agonism, these medications also stimulate the GIF receptor, making them particularly potent for inducing satiety and weight loss. Zeph-Bound is expected to enter Japan by the end of the year.
Other GLP-1 options like Trulicity and Lyxumia are also available, but their primary function is blood sugar control rather than weight loss.
Next time, I’ll introduce Dr. Hime’s top three GLP-1 recommendations. Stay tuned!